|Bid||6,200.00 x 0|
|Ask||7,500.00 x 0|
|Day's Range||7,219.00 - 7,315.00|
|52 Week Range||5,312.00 - 7,475.15|
|Beta (3Y Monthly)||1.05|
|PE Ratio (TTM)||42.38|
|Earnings Date||Oct 24, 2019|
|Forward Dividend & Yield||2.19 (3.02%)|
|1y Target Est||78.83|
AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. AstraZeneca today announced positive overall survival (OS) results from the Phase III FLAURA trial, a randomized, double-blinded, multicenter trial of TAGRISSO in previously-untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) mutations.
SALT LAKE CITY, Aug. 07, 2019 -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, today announced that the.
AstraZeneca and Merck’s LYNPARZA Met the Primary Endpoint of Significantly Increasing the Time Patients Selected for BRCA1/2 or ATM Mutations Live Without Radiographic Disease Progression vs.
(Bloomberg) -- The future looked bleak for Japanese drugmaker Daiichi Sankyo Co. when George Nakayama took over as chief executive officer in 2010.The stock was in the middle of a six-year free fall, its Indian subsidiary Ranbaxy Laboratories Ltd. was banned by the U.S. from selling products there, and a new anti-clotting medicine was slapped with the strictest safety warning.Nakayama, a former salesman for one of Japan’s biggest brewers, decided to reboot Daiichi Sankyo, pivoting away from generic medicines and toward the more lucrative business of cancer drugs. He sold scandal-ridden Ranbaxy for $3.2 billion, acquired two U.S.-based makers of cancer medicines and focused research on a class of drugs that could replace chemotherapy.Affirmation arrived in March, when British drugmaker AstraZeneca Plc agreed to pay as much as $6.9 billion to jointly develop one of those medicines, known as antibody drug conjugates, for patients of breast and other cancers. Under Nakayama’s turnaround plan, Daiichi Sankyo’s stock has rocketed 470% to an all-time high -- adding $37 billion in market value to make it Japan’s second-biggest drugmaker after Takeda Pharmaceutical Co.“So many things happened, but I was extremely lucky,” Nakayama, 69, said during a July 12 interview. “Looking back, it was a pretty tough start. It got better over time.”Soon after the deal, Nakayama ceded the CEO title to Sunao Manabe, a veterinarian by training, though Nakayama remains chairman. He’s leaving on a high note, with Daiichi Sankyo the best performer this year on an MSCI index of the biggest drugmakers. The stock climbed 0.7% to a fresh record on Tuesday, while Japan’s benchmark Topix index fell 0.4%.Analysts say the future looks bright for the Tokyo-based company, formed in 2005 through the merger of Daiichi Pharmaceutical Co. and Sankyo Co. Revenue is expected to increase 14% through 2023, while operating profit is seen surging 78%, according to analysts surveyed by Bloomberg.“The strategy shift is now starting to pay off,” said Yasuhiro Nakazawa, an analyst at SMBC Nikko Securities Inc. in Tokyo. “Daiichi Sankyo is really betting on the new direction as a whole.”That blueprint is anchored by the cancer drug known as DS-8201, which the company plans to seek U.S. approval for by Sept. 30. Daiwa Securities Co. analyst Kazuaki Hashiguchi predicts it will reach almost $8 billion in annual sales by 2030, surpassing Roche Holding AG’s breast-cancer drug Herceptin, which DS-8201 seeks to replace.The drug’s potential as a blockbuster medicine comes as global pharmaceutical giants are scrambling to transform themselves to replace aging pipelines. Cancer has become one of the hottest areas for deal activity between drug and biotechnology companies, as scientific advances are leading to new tailored therapies with strong growth potential.Daiichi Sankyo partnered with AstraZeneca to develop and commercialize DS-8201, and the two companies agreed to split profit and costs. Such ADCs are a class of drugs that can attack cancer cells in the body without damaging surrounding healthy ones. Analysts say DS-8201 could triple the number of patients who receive targeted treatment for breast cancer, which kills more than 500,000 women annually.“This Daiichi Sankyo drug has the potential to transform cancer care, so it is a very important product for us and, of course, for our partner,” Pascal Soriot, CEO of AstraZeneca, said in a July 25 interview on Bloomberg Television.Daiichi Sankyo is developing about a dozen cancer-fighting compounds, and considering further partnerships. It will devote a “significant portion” of its research budget toward successfully bringing them to the market, Manabe said in a July 9 interview. “Compared with a few years ago, our cancer pipeline is very rich now,” Manabe said.This new focus represents a sea change for Daiichi Sankyo, which was saddled with headaches when Nakayama took over. His early priority was to save Ranbaxy’s operations. Two of the Indian company’s four plants faced U.S. bans because of data fabrication, so Nakayama tried to strengthen the remaining two. His efforts fizzled, and they were banned by the U.S. starting in 2013.“We just couldn’t quite grasp the depth of Ranbaxy’s data falsification,” Nakayama said.Daiichi Sankyo found a buyer in Indian rival Sun Pharmaceutical Industries Ltd. in 2014. But its problems weren’t over. Daiichi Sankyo paid a $39 million fine in 2015 to settle U.S. allegations it gave kickbacks to doctors in exchange for prescribing company medicines. Most of the alleged infractions occurred before Nakayama’s tenure. That same year, its blood thinner edoxaban received U.S. approval but carried a “boxed warning” about use by certain patients, limiting its market potential.Shifting FocusNakayama decided the company needed a change, so he sold the Sun Pharmaceutical stake and shifted his focus to cancer drugs, overhauling operations, making acquisitions and hiring Antoine Yver, who ran the oncology unit at AstraZeneca, in April 2016.Daiichi Sankyo previously spent more than $1 billion to gain cancer medicines through takeovers of Plexxikon Inc. in 2011 and Ambit Biosciences Corp. in 2014, and its ADCs were showing promise in early testing.“The global oncology market became subdivided and not a single winner could take it all,” Nakayama said. “If we had the world-class science and acted fast, we had a chance.”The former CEO also takes a humble view of the company’s turnaround, giving some credit to fortune: in finding a buyer for Ranbaxy, having labs produce new compounds at the right time, latching onto AstraZeneca’s Yver to run the cancer business.“God made the timing well,” Nakayama said.To contact the reporters on this story: Kanoko Matsuyama in Tokyo at email@example.com;Grace Huang in Tokyo at firstname.lastname@example.orgTo contact the editors responsible for this story: Rachel Chang at email@example.com, Michael Tighe, Jeff SutherlandFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
AstraZeneca PLC (LON:AZN) is about to trade ex-dividend in the next 3 days. Ex-dividend means that investors that...
Bristol earnings and sales topped estimates Thursday, leading Bristol stock to jump. AstraZeneca stock popped after the pharmaceutical company beat expectations and raised its sales outlook.
AstraZeneca (AZN) reported its second-quarter earnings results on July 25. The stock is already up 6.39% on the day and is trading close to $42.91.
Major pharmaceutical giants acknowledge change is on the horizon amid mounting political pressures over costly medicine.
London markets made slight gains on Thursday as FTSE 100 miners rebounded and pharma giant AstraZeneca posted strong results.
The British drugmaker's shares rose more than 8% to hit a record high of 6,581 pence by 1423 GMT, bringing gains for the year so far to nearly 17% as Chief Executive Officer Pascal Soriot's turnaround plan gained traction. AstraZeneca, which maintained its dividend, reported a rise in drug sales for the fourth consecutive quarter after posting years of decline in sales due to patent losses on older drugs. "The momentum generated last year continued into the first half, consolidating AstraZeneca's return to growth based on the strength of our new medicines," Soriot said.
BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced it has signed an extension to a 2017 development agreement with AstraZeneca [NYSE:AZN] for BioCardia’s Helix™ biotherapeutic delivery catheter system. Under the terms of the initial pre-clinical phase of the relationship, BioCardia will receive a sizable upfront payment, a portion of which will be creditable to BioCardia biotherapeutic delivery systems, support and training. The agreement is exclusive with respect to a class of biotherapeutic agents that BioCardia is not currently developing on its own or with any other party and is time limited.
(Bloomberg) -- Drugmakers AstraZeneca Plc and Roche Holding AG joined major European rivals in raising their estimates for full-year results as new medicines begin to pay off.Sales and core earnings per share at Switzerland’s Roche will rise by a percentage in the mid- to high-single digits this year, the company said, as new drugs for cancer and multiple sclerosis offset pressure on older products. At Astra, product sales for the year are now expected to increase by a low double-digit percentage, helped by demand for the U.K. drugmaker’s roster of new cancer treatments. The stock surged in London trading.Like Astra and Swiss rival Novartis AG, Roche is seeing a handful of new medicines take over as the blockbusters that buoyed sales for a decade fade. Sales of Roche’s hemophilia therapy Hemlibra and Tecentriq for cancer breezed past analysts’ estimates in the first half. Astra’s cancer franchise saw sales surge by 51% last quarter amid demand for newcomers Lynparza and Imfinzi.GlaxoSmithKline Plc lifted its earnings forecast for the year on Wednesday, helped by a new shot for shingles that has quickly become a blockbuster. Glaxo is starting to encroach on Roche and Novartis’s turf by expanding into the cancer field. Novartis last week said earnings excluding some items would grow by a low double-digit to mid-teens percentage this year, the second boost to its estimate since the start of the year.Astra in ChinaRoche had previously nudged its estimate in April, saying it expected mid single-digit growth. The stock rose as much as 1.6% in Zurich trading. Glaxo gained as much as 1.9% in London, and Astra climbed as much as 6.5%, reaching a record.Astra’s second-quarter profit came in at 73 cents a share, well above analysts’ expectations, while net operating cash flow rebounded for the first half. The company remains open to acquisitions where it can add value, like its deal with Daiichi Sankyo Co. earlier this year for rights to a breast cancer drug, Chief Executive Officer Pascal Soriot said in an interview with Bloomberg TV.Sales in China, one of the company’s most important markets, rose 34%. Soriot had said earlier this year that performance there would be hurt in the second half by the country’s bulk-buying drug program for major cities.“The impact of those price pressures hasn’t been really coming as quickly as we thought initially, but they are coming,” he said in the interview.What Bloomberg Intelligence Says“We continue to see Astra as the preeminent large-pharma growth story.”\-- Sam Fazeli, pharma analystClick here to read the pieceRoche said its planned acquisition of Spark Therapeutics should close this year as it works with U.S. and U.K. regulators, but didn’t provide an explanation for the holdup.CEO Severin Schwan said the competition for Roche’s aging blockbuster cancer drugs will likely intensify in the fourth quarter. Rivals Amgen Inc. and Allergan Plc last week announced the availability of two cheaper biosimilar versions of Roche’s Avastin and Herceptin.In terms of stock performance, Novartis is ahead so far this year with a 23% gain. Glaxo has gained about 11% in the period, beating Roche’s and Astra’s 8% increases.(Updates with Astra CEO’s comments in sixth paragraph.)To contact the reporters on this story: Tim Loh in Munich at firstname.lastname@example.org;John Lauerman in London at email@example.comTo contact the editors responsible for this story: Eric Pfanner at firstname.lastname@example.org, Marthe Fourcade, Thomas MulierFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
AstraZeneca raised its second quarter product sales forecast and had strong sales from its cancer medicines. Sales from its oncology unit shot up to $2.17 billion and the top-selling lung cancer drug nearly doubled to $784 million. Yahoo Finance’s Dan Roberts, Kristin Myers and Sibile Marcellus discuss today’s trending ticker.
Jul.25 -- AstraZeneca Plc Chief Executive Officer Pascal Soriot speaks to Bloomberg after the U.K. drugmaker raised its annual sales forecast, helped by demand for its roster of new cancer drugs. He speaks on "Bloomberg Markets: European Open."